Mesoglycan
PreclinicalSmall molecule
Mesoglycan is one of 23 small molecule programs targeting Hemorrhoid. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Hemorrhoid
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Botox
RRevance Therapeutics, Inc.
Approved
Marcaine
IInnocoll
Approved
Ketalar
AAultman Health Foundation
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Nitrostat
VViatris Specialty LLC
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Celestone
SSchering-Plough
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mesoglycan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- FFederico II University